Analysts Are Bullish on Top Healthcare Stocks: AC Immune SA (ACIU), MoonLake Immunotherapeutics (MLTX)

view original post

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AC Immune SA (ACIUResearch Report), MoonLake Immunotherapeutics (MLTXResearch Report) and ProKidney (PROKResearch Report) with bullish sentiments.

AC Immune SA (ACIU)

BTIG analyst Thomas Shrader maintained a Buy rating on AC Immune SA yesterday and set a price target of $8.00. The company’s shares closed last Monday at $4.51.

According to TipRanks.com, Shrader is a 4-star analyst with an average return of 6.5% and a 37.8% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Coya Therapeutics, Inc., Acumen Pharmaceuticals, and ProMIS Neurosciences.

AC Immune SA has an analyst consensus of Strong Buy, with a price target consensus of $11.00.

See Insiders’ Hot Stocks on TipRanks >>

MoonLake Immunotherapeutics (MLTX)

BTIG analyst Julian Harrison maintained a Buy rating on MoonLake Immunotherapeutics yesterday and set a price target of $71.00. The company’s shares closed last Monday at $41.96.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 16.5% and a 49.4% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Apogee Therapeutics, Inc., and Mereo Biopharma Group Plc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MoonLake Immunotherapeutics with a $74.25 average price target, representing a 79.5% upside. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $66.00 price target.

ProKidney (PROK)

In a report released yesterday, Justin Zelin from BTIG reiterated a Buy rating on ProKidney, with a price target of $6.00. The company’s shares closed last Monday at $3.02, close to its 52-week low of $1.12.

According to TipRanks.com, Zelin is a 5-star analyst with an average return of 14.6% and a 38.2% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Precision BioSciences, and Poseida Therapeutics.

ProKidney has an analyst consensus of Moderate Buy, with a price target consensus of $5.33, which is a 61.0% upside from current levels. In a report released yesterday, Jefferies also assigned a Buy rating to the stock with a $6.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ACIU: